Funding agencies: This work was supported by the Medical Research Council UK (G0700943), Parkinson's UK (Grant 8047), the Cambridge NIHR Biomedical Research Centre, the Midlands Neuroscience Teaching and Research Fund, the Sandwell and West Birmingham Hospitals NHS Trust, the Ipsen Fund, the Wellcome Trust, and a Patrick Berthoud Clinical Research Fellowship and Raymond and Beverly Sackler studentship.
Version of Record online: 6 SEP 2012
Copyright © 2012 Movement Disorder Society
Volume 27, Issue 12, pages 1522–1529, October 2012
How to Cite
Kilarski, L. L., Pearson, J. P., Newsway, V., Majounie, E., Knipe, M. D. W., Misbahuddin, A., Chinnery, P. F., Burn, D. J., Clarke, C. E., Marion, M.-H., Lewthwaite, A. J., Nicholl, D. J., Wood, N. W., Morrison, K. E., Williams-Gray, C. H., Evans, J. R., Sawcer, S. J., Barker, R. A., Wickremaratchi, M. M., Ben-Shlomo, Y., Williams, N. M. and Morris, H. R. (2012), Systematic Review and UK-Based Study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Mov. Disord., 27: 1522–1529. doi: 10.1002/mds.25132
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue online: 18 OCT 2012
- Version of Record online: 6 SEP 2012
- Manuscript Accepted: 12 JUL 2012
- Manuscript Revised: 26 JUN 2012
- Manuscript Received: 27 OCT 2011
Additional Supporting Information may be found in the online version of this article.
|MDS_25132_sm_SuppTab1.doc||75K||Supporting Information Table 1. PINK1 (a), PARK2 (b), PARK7 (c) and LRRK2 (d) primers used for PCR amplification and sequencing.|
|MDS_25132_sm_SuppTab2.doc||29K||Supporting Information Table 2. Case Summary.|
|MDS_25132_sm_SuppTab3.doc||114K||Supporting Information Table 3. Overall proportions of cases with mutations in PARK2, PINK1 and PARK7 (including 95% confidence intervals in brackets).|
|MDS_25132_sm_SuppTab4.doc||54K||Supporting Information Table 4. Proportions of PARK2-positive cases among different patient sub-groups (including 95% confidence intervals in brackets).|
|MDS_25132_sm_SuppTab5.doc||43K||Supporting Information Table 5. Proportions of PINK1-positive cases among different patient sub-groups (including 95% confidence intervals in brackets).|
|MDS_25132_sm_SuppTab6.doc||34K||Supporting Information Table 6. Proportions of PARK7-positive cases among different patient sub-groups (including 95% confidence intervals in brackets).|
|MDS_25132_sm_SuppTab7.doc||30K||Supporting Information Table 7. Proportion of cases with PARK2 and PINK1 mutations in different ethnicities (including 95% confidence intervals in brackets).|
|MDS_25132_sm_SuppTab8.doc||95K||Supporting Information Table 8. Frequency of homozygous and compound heterozygous mutations in PARK2 and PINK1 (including 95% confidence intervals in brackets).|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.